We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+8.38%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$589M
AUM Growth
+$77.1M
Cap. Flow
+$17.1M
Cap. Flow %
2.91%
Top 10 Hldgs %
37.04%
Holding
153
New
41
Increased
30
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$19.2M
2
GILD icon
Gilead Sciences
GILD
+$15.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$11.6M
4
TSRO
TESARO, Inc.
TSRO
+$7.96M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.82M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$25.5M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.09M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$5.32M
4
NVS icon
Novartis
NVS
+$4.35M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$4.27M

Sector Composition

Rank Sector Weight
1 Healthcare 66.11%
2 Technology 6.31%
3 Industrials 2.63%
4 Communication Services 2.28%
5 Financials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SEDG icon
51
SolarEdge
SEDG
$2.51B
$3.42M 0.58%
171,018
+124,268
+266% +$2.2M
ADMS
52
DELISTED
Adamas Pharmaceuticals
ADMS
$3.42M 0.58%
195,500
– –
DBVT
53
DBV Technologies
DBVT
$799M
$3.22M 0.55%
9,017
– –
CRVS icon
54
Corvus Pharmaceuticals
CRVS
$1.12B
$3.12M 0.53%
257,665
-21,501
-8% -$230K
CTMX icon
55
CytomX Therapeutics
CTMX
$675M
$3.1M 0.53%
200,000
+50,000
+33% +$754K
SVRA icon
56
Savara
SVRA
$1.12B
$3.1M 0.53%
+526,315
New +$3.61M
TXMD icon
57
TherapeuticsMD
TXMD
$23.5M
$3.06M 0.52%
11,600
– –
EIGR
58
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.04M 0.52%
12,843
– –
OVID icon
59
Ovid Therapeutics
OVID
$414M
$3.04M 0.52%
+305,674
New +$3.99M
BLCM
60
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.92M 0.5%
25,000
+5,000
+25% +$621K
BOLD
61
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.87M 0.49%
+150,000
New +$2.4M
NBIX icon
62
Neurocrine Biosciences
NBIX
$16.8B
$2.85M 0.48%
62,000
-88,000
-59% -$4.27M
AAP icon
63
CALL
Advance Auto Parts
AAP
$3.35B
$2.8M 0.48%
250
+50
+25% +$6.87K
STML
64
DELISTED
Stemline Therapeutics, Inc.
STML
$2.76M 0.47%
300,000
– –
BCLI
65
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$2.76M 0.47%
+55,576
New +$3.43M
AXSM icon
66
Axsome Therapeutics
AXSM
$11.2B
$2.76M 0.47%
501,000
+100,000
+25% +$419K
CLSD
67
DELISTED
Clearside Biomedical
CLSD
$2.73M 0.46%
20,000
– –
ENDP
68
DELISTED
Endo International plc
ENDP
$2.68M 0.46%
+240,000
New +$2.82M
CYTK icon
69
Cytokinetics
CYTK
$10.5B
$2.64M 0.45%
217,990
+65,790
+43% +$914K
GNCA
70
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.56M 0.43%
61,250
-19,534
-24% -$940K
CASC
71
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.53M 0.43%
681,210
+100,000
+17% +$397K
SNA icon
72
Snap-on
SNA
$21.2B
$2.5M 0.42%
15,797
– –
LRCX icon
73
Lam Research
LRCX
$367B
$2.38M 0.41%
+168,600
New +$2.47M
FSTX
74
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.37M 0.4%
+43,750
New +$2.03M
ORCL icon
75
Oracle
ORCL
$374B
$2.37M 0.4%
+47,250
New +$2.15M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sphera Funds Management held 153 positions worth $589M, up 15% from $512M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Sphera Funds Management's Q2 2017 filing shows 41 new, 30 increased, 20 reduced and 25 closed positions. Its largest new stake was GSK: 360,000 shares worth $19.4M. The largest sale was Shire pic, an estimated $25.5M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

  • Sphera Funds Management's largest Q2 2017 buy was GSK: 360,000 shares worth $19.4M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $5.33M increase.
  • Sphera Funds Management's biggest Q2 2017 reduction was Shire pic, cutting an estimated $25.5M.
  • Sphera Funds Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2017, selling an estimated $7.09M.
  • Sphera Funds Management's ten largest holdings make up 37% of its $589M portfolio in Q2 2017.
  • Sphera Funds Management opened 41 new positions and closed 25 in Q2 2017.
  • Sphera Funds Management's portfolio value rose 15% quarter-over-quarter to $589M.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.